title: B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
abstract: BACKGROUND
  Contrast-induced nephropathy (CIN) is one of the leading causes of hospital-acquired renal failure and increase in the mortality and length of hospital stay after percutaneous coronary intervention (PCI).
  
  
  OBJECTIVE
  To evaluate the protective effect of B-type natriuretic peptide (BNP) on CIN in patients with heart failure undergoing PCI.
  
  
  METHODS
  In the prospective, placebo-controlled, randomized trial, 149 consecutive acute myocardial infarction (AMI) patients with heart failure undergoing primary PCI received recombinant human BNP (rhBNP) or placebo from the time of admission to 24 h after PCI. Serum creatinine (SCr) levels were measured to evaluate the protective effect of rhBNP on renal function. Estimated glomerular filtration rate (eGFR) was calculated by the simplified modification of diet in renal disease study equation. CIN was defined as a postprocedure peak increase in SCr of >0.5 mg/dl or >25% from baseline.
  
  
  RESULTS
  The baseline characteristics were similar in the two groups. The SCr significantly increased after PCI, with the peak value at 48 h, and then began to decrease. At day 7 after PCI, the SCr had lowered to the baseline level in the BNP group, but it failed to do so in the control group. At 24, 48, and 72 h and 7 days after PCI, the SCr was lower in the BNP group than that in the control group. The eGFR decreased significantly after PCI, with the lowest value at 48 h, and then it began to increase. The eGFR after PCI was higher in the rhBNP group than that in the control group. The occurrence of CIN was significantly lower in the rhBNP group than in the control group.
  
  
  CONCLUSIONS
  Periprocedural use of BNP could further promote the recovery of renal function and decrease the occurrence of CIN compared with routine treatment alone in patients with heart failure undergoing primary PCI.
authors.affiliation: Cardiology Interventional Center, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Xianghua
authors.initials: X
authors.lastname: Fu
authors.forename: Xinwei
authors.initials: X
authors.lastname: Jia
authors.forename: Xinna
authors.initials: X
authors.lastname: Fan
authors.forename: Xinshun
authors.initials: X
authors.lastname: Gu
authors.forename: Shiqiang
authors.initials: S
authors.lastname: Li
authors.forename: Weili
authors.initials: W
authors.lastname: Wu
authors.forename: Weize
authors.initials: W
authors.lastname: Fan
authors.forename: Jianling
authors.initials: J
authors.lastname: Su
authors.forename: Guozhen
authors.initials: G
authors.lastname: Hao
authors.forename: Yunfa
authors.initials: Y
authors.lastname: Jiang
authors.forename: Ling
authors.initials: L
authors.lastname: Xue
mesh_terms: D000368:Aged; D017130:Angioplasty; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000097:blood / Q000601:surgery*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use*; D020011:Protective Agents / Q000627:therapeutic use*
chemical_list: D003287:Contrast Media; D020011:Protective Agents; D020097:Natriuretic Peptide, Brain; D003404:Creatinine